CV Raúl J. Andrade
Raúl J. Andrade Bellido
Catedrático de Universidad
Tel: 952131615 E-mail: andrade@uma.es
Despacho: Facultad de Medicina. Planta baja
Biosketch
Raúl J. Andrade is Professor of Medicine and Director of the Department of Medicine at the University of Malaga. Director of the Gastroenterology Service, University Hospital of Málaga. Founder and director of the Spanish Drug Induced Liver Injury (DILI) Registry (www.spanishdili.uma.es) -the first network specialized in the study of Drug Induced Liver Injury- and of the Spanish Latin-American DILI Network and the recently set-up Prospective European DILI Registry awarded by the European Association for the Study of the Liver (EASL). Appointed by the EASL as Chairman of the Clinical Practice Guidelines Council responsible for writing a new CPG on Drug Induced Liver Injury 2016. Chair of CIOMS (Council for International Organizations of Medical Sciences) working group on DILI 2017. Chair COST ACTION CA17112. Principal investigator of CIBERehd group. He leads the PAIDI CTS-1032 group, IP of IBIMA Group on Translational Clinical Pharmacology, Expert of the World Health Organization, the European Medicines Agency (EMA) and the Spanish Medicines Agency in the Evaluation of liver safety of drugs. Member of the steering committee of the Group of Special Interest in Hepatotoxicity (AASLD). Member of the working team on the Cholestatic and Drug-induced Liver Disease section of the EASL- HEPAMAP project. He is member of the expert panel of the EFSA (European Food Safety Authority) since 2016. Member of the Reviewing board for the EASL International Liver Congress (2013-2016). Partner of the H2020 JTI IMI TRANSBIOLINE project, and the COST grant proposal Prospective European Drug-Induced Liver Injury Network.
Invited speaker in international meetings such as: Gordon Research Conference, Maine, USA (2008); NIH Workshop: Drug-Induced Injury: Standardization of nomenclature and causality assessment (Maryland, USA 2008); EASL Postgraduate course Cholestatic disease of the liver and bile ducts , (Berlin, Germany 2011); EASL – IASL JOINT SYMPOSIUM: Drug Induced Liver Disease: Global perspective, (London 2014); Co-Chair Meet-The Professor Lunch at the AASLD(Boston, USA 2014); SYMPOSIUM OF THE IUPHAR-CD - EACPT: "Clinical Networks and Consortia in Drug-Induced Liver Injury (DILI): an opportunity for advancing Safety Sciences" (Madrid, 2015); EASL/AASLD Monothematic Conference on Autoimmune Hepatitis (London, 2015); Japan Digestive Disease Week (Tokyo, 2015); 5th Symposium Hepatology 2015 on Drug-Induced Liver Injury (Switzerland, 2015); EASL Monothematic Conference onNASH (Riga, Latvia 2016); the AASLD Liver Meeting (Boston, USA, 2016). The 26th Conference of the APASL (Shanghai 2017); International Conference on Fatty Liver (Sevilla, Spain 2017); EASL Monothematic Conference Cholangyocites in health and Disease: from basic Science to novel treatments (Oslo, Norway 2017). Expert Panel Member Breakfast morning rounds: Drug-induced liver injury - How to diagnose, how to treat? and Clinical Practice Guidelines session: “Drug-Induced Liver Injury” at the EASL Meeting (Paris, France 2018). EASL-INASL Symposium on DILI (Delhi 2018). “Analysis of drug-induced toxicity” at the FIP World Congress (Glasgow 2018) China-CIOMS session meeting on DILIN (Beijing and Chongqin 2018). Drug-Induced Liver Injury: “Advances in Diagnosis and Clinical Management” at the 26th United Gastroenterology Week (Vienna 2018). Special Interest Group in Hepatotoxicity Meeting at the AASLD Liver Meeting (San Francisco, USA, 2018). Expert Panel Member Breakfast morning rounds: “Immune mediated hepatitis” and Co-Chair and Speaker EASL-ALEH session: “DILI and drug safety in cirrhosis” at the EASL Meeting (Vienna 2019). “Drug-herb and dietary supplement-induced Liver injury at the World Congress of Gastroenterology (Istambul 2019). Management of drug-induced liver injury: “Epidemiology and Diagnosis” and “Biomarkers for Drug-Induced Liver Injury” at the 27th United Gastroenterology Week (Barcelona 2019). FDA Liver Seminars “Drug-induced liver injury guidelines and clinical studies: the European perspective” (White Oak Campus, Silver Spring, Maryland USA 2019). “DILI: update and practical management” at the 4th Swiss Hepatology Postgraduate Course (Vevey, 2019). 5th Sino-America International Symposium on Drug-Induced Liver Injury and 6th National Conference in Drug-Induced Liver Injury (Shanghai 2019).
Prof. Andrade is Associate editor of Liver International (Q1) and member of the editorial board of: Hepatology (2012-2016) (D1) and Frontiers in Pharmacology (Q1). He published over 250 articles in peer-review journals, and 43 book chapters. He has an h-index of 47 and 9509 total citations by 6161 documents. 23 publications were cited more than 100 times and 40 original articles received more than 50 citations. He presented more than 340 communications in International & National Scientific Meetings. In the past 5 years, he has directed 10 PhD thesis included 2 international thesis.
